



Press Release, September 15, 2020

## **Diamyd Medical has received USD 13.9 million in connection with its divestment in Companion Medical**

Diamyd Medical announces today that in connection with the previously announced acquisition of Companion Medical, Inc by Medtronic plc., Diamyd Medical has now received approximately USD 13.9 million, corresponding to SEK 120 million. Depending on achievement of certain future milestones, some additional payments may be possible, and will then be communicated if they occur.

### **About Diamyd Medical**

Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined subgroup in a large-scale metastudy as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine is administered directly into a lymph node in children and young adults with newly diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: [info@fnca.se](mailto:info@fnca.se).

### **For further information, please contact:**

Ulf Hannelius, President and CEO  
Phone: +46 736 35 42 41  
E-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)

### **Diamyd Medical AB (publ)**

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68  
E-mail: [info@diamyd.com](mailto:info@diamyd.com) Reg. no.: 556242-3797 Website: <https://www.diamyd.com>

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.15 CET on September 15, 2020.